Coleus Forskohlii — Benefits Deep Dive

This herb sits in an unusual position, and the gap it straddles is the reason these four pages exist. Forskolin, the molecule in the root of Plectranthus barbatus — still traded everywhere as Coleus forskohlii, and known in Ayurveda as makandi — is a genuine and important pharmacological agent. It activates an enzyme called adenylyl cyclase directly, raising the universal cell signal cyclic AMP without needing a hormone or a receptor. There is a solved crystal structure showing how it does it. It is a standard positive control in cell biology laboratories on every continent, it appears in tens of thousands of published methods sections, and a chemically modified, water-soluble relative of it is an approved intravenous heart-failure drug in Japan. None of that is marketing.

And the reason most people arrive here — that a coleus capsule burns fat — is not supported. The human evidence is a handful of small, short trials that disagree with each other. The most-quoted positive study found a shift in body composition in thirty men without meaningful weight loss; a companion trial in twenty-three women found no fat loss at all; a later trial adding the extract to a calorie-reduced diet found no between-group difference. Reviews of supplements for obesity place forskolin in the insufficient-evidence category. Evidence tier for weight loss: NOT SUPPORTED.

Those two paragraphs are not in tension — the second follows from the first. The property that makes forskolin a superb laboratory reagent is that it works in any cell, because it skips the receptor that would otherwise give a drug its address. In a culture dish that universality is a gift. Swallowed, it means the same molecule is raising cyclic AMP in your blood vessels, your platelets, your stomach lining and your thyroid at the same time as your fat cells. That is not a fat-loss mechanism; it is an unselective systemic signalling change, and it is also the origin of every safety caution on these pages — lowered blood pressure, impaired platelet function, increased gastric acid, and one absolute contraindication in polycystic kidney disease.

What follows is that story in four parts: the mechanism told properly, the weight-loss claim examined without flinching, the legitimate clinical research strands reported and firmly fenced off from the marketing, and the safety profile derived from first principles.

Table of Contents

1. Deep-Dive Articles
2. The Short Version
3. What Is Supported, What Is Not
4. Why the Route of Administration Decides Everything
5. Key Research: Mechanism and Adenylyl Cyclase
6. Key Research: Body Composition and Weight
7. Key Research: Intraocular Pressure and Glaucoma
8. Key Research: Airways and the Failing Heart
9. Key Research: Safety, Interactions and Toxicology
10. External Resources
11. Connections

Deep-Dive Articles

The Short Version

If you read nothing else:

1. The plant. Plectranthus barbatus, mint family, native to India and tropical East Africa. The root is the part used — forskolin is essentially absent from the leaves. Ayurvedic name makandi; also garmar in Gujarati. Still sold universally as Coleus forskohlii.
2. The molecule is real and important. Forskolin activates adenylyl cyclase directly, raising cyclic AMP without a receptor. That is textbook pharmacology with a crystal structure behind it, and it is why the compound is a global laboratory standard. Tier: established biochemistry.
3. Weight loss: NOT SUPPORTED. A small number of short trials, disagreeing, none showing meaningful weight loss. Expected effect on the scale, on current evidence: approximately zero.
4. Two clinical strands are legitimate and separate. Intraocular pressure lowering (topical drops, and oral multi-ingredient add-on studies) and bronchodilation (inhaled powder). Tier: preliminary human data, non-oral routes. Neither supports the supplement, and neither is standard care anywhere.
5. The safety profile follows from the mechanism. Lowers blood pressure; inhibits platelet aggregation; increases gastric acid secretion; theoretical concerns with nitrates, vasodilators and erectile-dysfunction drugs; animal evidence of dose-related liver injury and cytochrome induction; contraindicated in polycystic kidney disease and in pregnancy; stop two weeks before surgery.
6. There is no long-term human safety data. The trials ran twelve weeks. Indefinite use is unstudied.
7. Products vary. The studied material was a 10% standardised root extract. Higher percentages are larger untested doses, not better products, and a label saying only "coleus" is not an adequate botanical identification.

What Is Supported, What Is Not

Every claim on these pages carries an evidence tier. Collected in one place:

• Established biochemistry — forskolin directly activates adenylyl cyclase, raising cyclic AMP receptor-independently in nearly any cell type; it is a standard laboratory positive control; 1,9-dideoxyforskolin from the same root does not activate the enzyme and serves as the matching negative control.
• Established pharmacology, non-oral routes — blood-pressure lowering and increased cardiac contractility by intravenous infusion under monitoring; a water-soluble derivative approved intravenously for acute heart failure in Japan; antiplatelet activity in human platelets; increased gastric acid secretion in isolated gastric tissue.
• Preliminary human data, topical route — forskolin eye drops lowered intraocular pressure in early studies including human volunteers; a modern 1% drop preparation was tested open-label. Not approved therapy anywhere.
• Preliminary human data, inhaled route — inhaled dry-powder forskolin produced measurable bronchodilation in small asthma studies. No inhaler was ever developed.
• Preliminary, small, multi-ingredient, geographically clustered — oral forskolin-plus-rutin combination products as an add-on in glaucoma patients already at maximum tolerated drops. No effect can be assigned to forskolin alone.
• Preliminary, in vitro and animal — lipolysis in isolated fat cells; steroidogenesis in isolated cells; anti-metastatic activity resting on the antiplatelet effect; dose-related liver injury and cytochrome induction in mice.
• Traditional use only — heart and respiratory complaints, digestive problems, and urinary stones as a pashanabhedi or "stone-breaker" herb. That name has most often been assigned to a different plant altogether, so even the traditional lineage is less clean than marketing implies.
• NOT SUPPORTED — weight loss and fat loss from oral supplementation; oral coleus as treatment for asthma, glaucoma, high blood pressure or heart failure; the idea that an approved intravenous or topical use demonstrates oral safety.

Why the Route of Administration Decides Everything

This idea recurs on all four pages, so it is worth stating once, plainly: a different route of administration is a different intervention. Changing how a compound enters the body changes the concentration reached at the target, the speed of arrival, how much is destroyed on the way, and which other tissues are exposed. Route is not packaging. Route is part of the drug.

Forskolin makes the point better than almost any other compound, because its strongest evidence comes from three routes that all avoid the oral problem:

• Eye drops — a tiny quantity onto the cornea; high local concentration, negligible systemic exposure.
• Inhaled dry powder — delivered onto airway smooth muscle, which is the target; fast, local, low systemic dose.
• Intravenous infusion — the whole dose into the bloodstream at a controlled rate, under continuous monitoring, and using a chemically redesigned water-soluble molecule rather than forskolin itself.
• A swallowed capsule — must survive the stomach, cross the gut wall despite being essentially water-insoluble, then pass through a liver built to dismantle exactly this class of greasy plant diterpene. No well-replicated human account of the resulting blood concentration has been published.

That last absence is the single most useful fact about this supplement category, and it is never on a label. It also means the argument runs both ways: the non-oral successes are not evidence that a capsule works, and they are not evidence that a capsule is safe.

Key Research: Mechanism and Adenylyl Cyclase

Throughout these pages, citations are given as author, title, journal and year in plain text, with the link pointing at a PubMed topic search rather than a numeric identifier — so a link can never silently resolve to the wrong paper.

1. Rall TW, Sutherland EW. Formation of a cyclic adenine ribonucleotide by tissue particles. Journal of Biological Chemistry, 1958. The discovery of cyclic AMP, and the origin of the second-messenger concept. PubMed search
2. Bhat SV, Bajwa BS, Dornauer H, de Souza NJ, Fehlhaber HW. Structures and stereochemistry of new labdane diterpenoids from Coleus forskohlii Briq. Tetrahedron Letters, 1977. The isolation and structure of the compound, then named coleonol. PubMed search
3. Seamon KB, Padgett W, Daly JW. Forskolin: unique diterpene activator of adenylate cyclase in membranes and in intact cells. Proceedings of the National Academy of Sciences of the USA, 1981. The paper that made forskolin a universal laboratory reagent. PubMed search
4. Laurenza A, Sutkowski EM, Seamon KB. Forskolin: a specific stimulator of adenylyl cyclase or a diterpene with multiple sites of action? Trends in Pharmacological Sciences, 1989. An early, candid account of forskolin's off-target effects. PubMed search
5. Tesmer JJ, Sunahara RK, Gilman AG, Sprang SR. Crystal structure of the catalytic domains of adenylyl cyclase in a complex with Gs-alpha and GTP-gamma-S. Science, 1997. Forskolin resolved in its binding pocket at the interface between the enzyme's two catalytic halves. PubMed search
6. Dessauer CW, Watts VJ, Ostrom RS, Conti M, Dove S, Seifert R. International Union of Basic and Clinical Pharmacology: structures and small molecule modulators of mammalian adenylyl cyclases. Pharmacological Reviews, 2017. The current authoritative survey of the enzyme family. PubMed search

Key Research: Body Composition and Weight

1. Godard MP, Johnson BA, Richmond SR. Body composition and hormonal adaptations associated with forskolin consumption in overweight and obese men. Obesity Research, 2005. Thirty men, twelve weeks, 250 mg of 10% extract twice daily: favourable composition shift, no meaningful weight change. PubMed search
2. Henderson S, Magu B, Rasmussen C, et al. Effects of Coleus forskohlii supplementation on body composition and hematological profiles in mildly overweight women. Journal of the International Society of Sports Nutrition, 2005. Twenty-three women, same dose and duration: no promotion of fat loss. PubMed search
3. Loftus HL, Astell KJ, Mathai ML, Su XQ. Coleus forskohlii extract supplementation in conjunction with a hypocaloric diet reduces the risk factors of metabolic syndrome in overweight and obese subjects: a randomized controlled trial. Nutrients, 2015. No meaningful between-group difference in weight or fat loss when added to a calorie-reduced diet. PubMed search
4. Litosch I, Hudson TH, Mills I, Li SY, Fain JN. Forskolin as an activator of cyclic AMP accumulation and lipolysis in rat adipocytes. Molecular Pharmacology, 1982. The in-vitro lipolysis observation the entire claim rests on. PubMed search
5. Wolfe RR, Klein S, Carraro F, Weber JM. Role of triglyceride–fatty acid cycle in controlling fat metabolism in humans during and after exercise. American Journal of Physiology, 1990. Human measurement of the re-esterification cycle that makes lipolysis and fat loss non-equivalent. PubMed search
6. Ríos-Hoyo A, Gutiérrez-Salmeán G. New dietary supplements for obesity: what we currently know. Current Obesity Reports, 2016. Places forskolin among agents with plausible mechanisms and inadequate human data. PubMed search
7. Batsis JA, Apolzan JW, Bagley PJ, et al. A systematic review of dietary supplements and alternative therapies for weight loss. Obesity, 2021. Broad systematic assessment of the supplement evidence base. PubMed search

Key Research: Intraocular Pressure and Glaucoma

1. Caprioli J, Sears M. Forskolin lowers intraocular pressure in rabbits, monkeys, and man. The Lancet, 1983. The founding topical eye-drop observation — note the route. PubMed search
2. Caprioli J, Sears M, Bausher L, Gregory D, Mead A. Forskolin lowers intraocular pressure by reducing aqueous inflow. Investigative Ophthalmology and Visual Science, 1984. Establishes reduced production rather than improved drainage. PubMed search
3. Pescosolido N, Librando A. Oral administration of an association of forskolin, rutin and vitamins B1 and B2 potentiates the hypotonising effects of pharmacological treatments in primary open-angle glaucoma patients. Clinica Terapeutica, 2010. An early oral combination add-on study. PubMed search
4. Vetrugno M, Uva MG, Russo V, et al. Oral administration of forskolin and rutin contributes to intraocular pressure control in primary open angle glaucoma patients under maximum tolerated medical therapy. Journal of Ocular Pharmacology and Therapeutics, 2012. The most-cited oral add-on study; multi-ingredient, so no effect can be assigned to forskolin alone. PubMed search
5. Majeed M, Nagabhushanam K, Natarajan S, et al. Efficacy and safety of 1% forskolin eye drops in open angle glaucoma: an open-label study. Saudi Journal of Ophthalmology, 2015. A modern topical preparation, tested without blinding. PubMed search

Key Research: Airways and the Failing Heart

1. Lichey J, Friedrich T, Priesnitz M, et al. Effect of forskolin on methacholine-induced bronchoconstriction in extrinsic asthmatics. The Lancet, 1984. Bronchoprotection in a challenge protocol. PubMed search
2. Bauer K, Dietersdorfer F, Sertl K, Kaik B, Kaik G. Pharmacodynamic effects of inhaled dry powder formulations of fenoterol and colforsin in asthma. Clinical Pharmacology and Therapeutics, 1993. The clearest bronchodilator signal — by inhalation, head-to-head against a beta-2 agonist. PubMed search
3. González-Sánchez R, Trujillo X, Trujillo-Hernández B, et al. Forskolin versus sodium cromoglycate for prevention of asthma attacks: a single-blinded clinical trial. Journal of International Medical Research, 2006. The one oral asthma trial; weak design, weak comparator, unreplicated. PubMed search
4. Baumann G, Felix S, Sattelberger U, Klein G. Cardiovascular effects of forskolin in patients with idiopathic congestive cardiomyopathy: a comparative study with dobutamine and sodium nitroprusside. Journal of Cardiovascular Pharmacology, 1990. Intravenous, monitored, against two standard agents. PubMed search
5. Dekkers JF, Wiegerinck CL, de Jonge HR, et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids. Nature Medicine, 2013. The forskolin-induced swelling assay — forskolin as a translational tool that can inform an individual patient's treatment. PubMed search

Key Research: Safety, Interactions and Toxicology

1. Lindner E, Dohadwalla AN, Bhattacharya BK. Positive inotropic and blood pressure lowering activity of a diterpene derivative isolated from Coleus forskohlii: forskolin. Arzneimittel-Forschung, 1978. The blood-pressure effect is in the compound's founding literature. PubMed search
2. Siegl AM, Daly JW, Smith JB. Inhibition of aggregation and stimulation of cyclic AMP generation in intact human platelets by the diterpene forskolin. Molecular Pharmacology, 1982. The antiplatelet effect, in human platelets. PubMed search
3. Chew CS. Forskolin stimulation of acid and pepsinogen secretion in isolated gastric glands. American Journal of Physiology, 1983. Increased gastric acid secretion — the reason ulcer and reflux disease appear in the cautions. PubMed search
4. Yamaguchi T, Nagao S, Wallace DP, et al. Cyclic AMP activates B-Raf and ERK in cyst epithelial cells from autosomal-dominant polycystic kidneys. Kidney International, 2003. Why cAMP elevation is exactly the wrong thing in polycystic kidney disease. PubMed search
5. Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. New England Journal of Medicine, 2012. The approved drug for that disease works by lowering cAMP — the mechanism read in reverse. PubMed search
6. Virgona N, Taki Y, Yamada S, Umegaki K. Dietary Coleus forskohlii extract generates dose-related hepatotoxicity in mice. Journal of Applied Toxicology, 2013. An animal liver signal for a supplement with no long-term human safety data. PubMed search
7. Reports from Japanese pharmacology groups around 2012 that coleus extract induces hepatic cytochrome P450 enzymes and that this induction mediates an interaction with warfarin — running opposite to forskolin's antiplatelet effect, so the net direction in a given person is unpredictable. Given as a topic search so the details can be checked at source. PubMed search
8. Ammon HP, Müller AB. Forskolin: from an ayurvedic remedy to a modern agent. Planta Medica, 1985. A contemporaneous review spanning the compound's effects across tissues. PubMed search

Live PubMed Searches

1. forskolin + adenylyl cyclase + mechanism
2. coleus forskohlii + body composition + randomized
3. forskolin + intraocular pressure
4. forskolin + bronchodilation + asthma + inhaled
5. coleus forskohlii + safety + adverse effects
6. forskolin + platelet aggregation inhibition
7. forskolin + pharmacokinetics + humans
8. cyclic AMP + cyst growth + polycystic kidney disease
9. Plectranthus barbatus + phytochemistry
10. colforsin daropate + acute heart failure

External Resources

• NIH Office of Dietary Supplements — US government fact sheets on supplements for weight loss, and on how supplement regulation actually works.
• National Center for Complementary and Integrative Health — appraisals of botanical evidence and safety, and guidance on telling your clinicians what you take.
• PubChem — the chemical record for forskolin: structure, properties, computed solubility.
• RCSB Protein Data Bank — solved structures, including the adenylyl cyclase catalytic core with forskolin bound.
• ClinicalTrials.gov — search "forskolin" to see what has and has not been registered as a trial.
• MedlinePlus — plain-language drug and supplement information from the US National Library of Medicine.
• US Federal Trade Commission — consumer guidance on deceptive weight-loss advertising, a documented problem in this specific product category.
• National Eye Institute — glaucoma information, and why proven pressure-lowering treatment must not be delayed.

Connections

• All Herbs
• Coleus forskohlii (Forskolin) — the main topic page: botany, naming, traditional use, active compounds, culinary use, forms, dosage and cautions.
• Forskolin and Cyclic AMP — the mechanism, told properly, and why universality is a liability.
• Forskolin for Weight Loss — the claim examined trial by trial. Verdict: NOT SUPPORTED.
• Glaucoma, Asthma and Clinical Research — the legitimate strands, and the fence around them.
• Safety, Blood Pressure and Interactions — the risks, derived from the mechanism rather than guessed.
• Weight Loss — the evidence-based hub: energy balance, satiety, adherence and maintenance.
• Why Diets Fail — the physiology of regain, and why a pill is the wrong place to look.
• Obesity — the medical picture and when evaluation is warranted.
• Metabolic Syndrome — the cluster the 2015 coleus trial actually reported on.
• Glaucoma — the disease, why pressure control is the only proven intervention, and why delay is irreversible.
• Asthma — reliever and preventer therapy, and why substitution is dangerous.
• Hypertension — additive blood-pressure lowering, and what treats high blood pressure properly.
• Heart Failure — where a water-soluble forskolin derivative is used intravenously in one country.
• Polycystic Kidney Disease — the absolute contraindication, and the disease that explains why.
• Peptic Ulcer Disease — increased acid plus impaired platelets is the worst combination.
• GERD — reflux, and a supplement that raises acid output.
• Hypothyroidism — the TSH receptor signals through cAMP, the basis of the theoretical thyroid interaction.
• Berberine — another plant compound with a real mechanism and marketing that outruns it.
• EGCG — green tea catechin sold on similar thermogenic reasoning; a useful comparison in evidence weighing.
• Green Tea — the whole-food version of that story.
• Chanca Piedra — another "stone-breaker" herb, with its own honest evidence appraisal.
• Asthma Attack Visualization — interactive bronchoconstriction and what relieves it.
• Blood Pressure Visualization — interactive look at vascular tone and its regulation.

Safety note and disclaimer. These pages are educational and are not medical advice. Coleus forskohlii is not established as effective for weight loss or for any other consumer indication, and it is not risk-free: it lowers blood pressure, it inhibits platelet aggregation and adds to anticoagulant and antiplatelet drugs, it increases gastric acid secretion, animal studies show dose-related liver injury and induction of drug-metabolising enzymes, and it is contraindicated in polycystic kidney disease and in pregnancy. Stop it at least two weeks before any surgery or dental procedure. There is no long-term human safety data. Never put a supplement in your eye, and never delay or replace proven treatment for glaucoma, asthma, high blood pressure, heart disease or kidney disease with a supplement. Tell every prescriber and pharmacist what you take.

Back to Table of Contents